Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|July 20, 2023

JAK Inhibitor Overview and Relevance to AD

Author(s)Christopher G. Bunick, MD, PhD, Ruth Ann Vleugels, MD, MPH, MBA

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).

Episodes in this series

EP. 1 JAK Inhibitor Overview and Relevance to AD

EP. 1 JAK Inhibitor Overview and Relevance to AD

EP. 2 Comparing Current Treatment Agents for AD

EP. 2 Comparing Current Treatment Agents for AD

EP. 3 Clinical Experience With JAK Inhibitor in AD

EP. 3 Clinical Experience With JAK Inhibitor in AD

EP. 4 Experts Present Background on Long-Term Safety Study of Upadacitinib for AD

EP. 4 Experts Present Background on Long-Term Safety Study of Upadacitinib for AD

EP. 5 Experts on Results of Long-Term Safety Study of Upadacitinib for AD

EP. 5 Experts on Results of Long-Term Safety Study of Upadacitinib for AD

EP. 6 Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD

EP. 6 Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD

EP. 7 Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents

EP. 7 Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents

EP. 8 Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 8 Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 9 Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 9 Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 10 Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline

EP. 10 Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline

EP. 11 Box Warning and JAK Inhibitor

EP. 11 Box Warning and JAK Inhibitor

EP. 12 JAK Inhibitor Selectivity

EP. 12 JAK Inhibitor Selectivity

EP. 13 Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 13 Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 14 Evolving the Standard of Care for AD: Safety and Treatment Response

EP. 14 Evolving the Standard of Care for AD: Safety and Treatment Response

EP. 15 Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

EP. 15 Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

EP. 16 AD Endotypes and Outcomes

EP. 16 AD Endotypes and Outcomes

EP. 17 Final Thoughts on JAK Inhibitor for AD

EP. 17 Final Thoughts on JAK Inhibitor for AD

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Jared Gollob, MD

STAT6 Degradation by KT-621 Correlates With Itch and Lesion Reduction in AD

ByJared Gollob, MD,Kaitlyn Bader, Assistant Managing Editor

June 3rd 2026

Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim

ByMaddi Hebebrand, MC, Associate Editor

June 1st 2026

Soquelitinib Demonstrates Efficacy in Atopic Dermatitis After Systemic Failure

ByAlbert Chiou, MD, MBA,Kaitlyn Bader, Assistant Managing Editor

May 28th 2026

Zumilokibart Meets Primary and Secondary Endpoints in Phase 2 AD Trial

ByMaddi Hebebrand, MC, Associate Editor

May 27th 2026

JADE EXTEND Data Show Abrocitinib Efficacy Holds and Deepens Through 2 Years of Treatment

ByMaddi Hebebrand, MC, Associate Editor

May 26th 2026

Latest CME

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen

Social Media Mythbusters: Hypochlorous Acid Sprays

Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy

SkinJect Advances into Registrable Development as Potential First-in-Class Therapy for Gorlin Syndrome

Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim